fact
transfus
could
transmit
infecti
diseas
name
bacteri
infect
syphili
hepat
recogn
taa
progress
intervent
date
back
dawn
blood
bank
donor
test
antibodi
syphili
began
bacteri
infect
major
threat
time
world
war
ii
later
decreas
cold
storag
whole
blood
red
blood
cell
rbc
plastic
hepat
tah
larg
prevent
near
elimin
paid
donat
product
label
identifi
paid
collect
concurr
test
hepat
b
viru
hbv
howev
medic
import
residu
hepat
risk
mostli
attribut
hepat
nanbh
recogn
acut
threat
bacteri
infect
larg
control
syphili
effect
prevent
full
consequ
nanbh
transmiss
unappreci
blood
commun
late
focus
system
issu
econom
competit
suppli
instabl
transmiss
diseas
came
aid
aid
first
report
immun
defici
soon
identifi
risk
group
includ
sex
worker
haitian
entrant
unit
state
inject
drug
evid
transfus
transmiss
emerg
case
aid
report
hemophilia
patient
later
transfus
recipi
howev
despit
number
feder
meet
action
nation
govern
contain
aid
risk
transfus
undertaken
although
transfus
transmiss
hiv
undoubtedli
took
place
least
year
recognit
taa
due
long
asymptomat
period
diseas
delay
respons
taa
subsequ
initi
report
diseas
person
hemophilia
transfus
recipi
also
contribut
aid
tragedi
rage
within
hemophilia
commun
due
fact
transmiss
fatal
infect
failur
author
provid
adequ
warn
prevent
express
demand
congression
investig
member
congress
instead
direct
depart
health
human
servic
hh
look
matter
accomplish
contract
institut
medicin
iom
studi
evolv
event
impact
blood
safeti
process
crisi
period
report
entitl
hiv
blood
suppli
analysi
crisi
decis
make
iom
found
wrongdo
organ
offici
identifi
fail
opportun
better
protect
public
health
failur
act
rapidli
aggress
face
taa
seen
unmask
underli
weak
abil
feder
agenc
address
new
threat
face
substanti
scientif
uncertainti
weak
attribut
system
defici
primarili
leadership
coordin
particular
iom
critic
feder
agenc
lack
leadership
need
overcom
inher
bureaucrat
inertia
absenc
systemat
approach
within
advisori
committe
suffici
maintain
focu
depend
regul
industri
sourc
data
given
inher
conflict
interest
failur
engag
forward
think
respect
new
technolog
emerg
safeti
threat
consequ
risk
taa
sever
underestim
patient
care
provid
suitabl
warn
risk
resist
chang
statu
quo
caus
delay
intervent
set
recommend
direct
primarili
feder
agenc
iom
call
respons
integr
process
includ
establish
blood
safeti
council
report
design
blood
safeti
director
within
hh
stand
expert
panel
assur
commun
blood
product
risk
altern
use
care
provid
public
specif
food
drug
administr
fda
iom
recommend
uncertainti
countervail
public
health
concern
preclud
elimin
potenti
risk
fda
encourag
necessari
requir
blood
industri
implement
partial
solut
littl
risk
caus
harm
mandat
iom
admonit
fda
institut
measur
precaut
face
uncertainti
becom
domin
factor
blood
safeti
decis
make
vigil
proactiv
fda
approach
blood
safeti
unfortun
unintend
consequ
dramat
increas
manufactur
cost
therefor
price
hh
respons
iom
report
establish
new
landscap
feder
oversight
blood
system
continu
present
day
present
structur
includ
assist
secretari
health
ash
blood
safeti
director
head
public
health
servic
relat
agenc
member
blood
organ
tissu
safeti
execut
council
botsec
hh
secretari
advisori
committe
blood
tissu
safeti
avail
formerli
advisori
committe
blood
safeti
avail
ash
acknowledg
nation
blood
safeti
director
final
respons
author
decis
regard
blood
safeti
avail
interag
blood
organ
tissu
safeti
work
group
meet
monthli
teleconfer
often
necessari
botsec
meet
approxim
quarterli
face
face
ash
provid
inform
guidanc
regard
current
emerg
issu
involv
nation
blood
unlik
fda
blood
product
advisori
committe
whose
function
provid
extern
scientif
advic
relev
regul
secretari
advisori
committe
empow
discuss
broad
legal
ethic
social
econom
issu
affect
blood
system
give
voic
patient
concern
advisori
committe
seat
vote
repres
commun
particularli
affect
taa
addit
respons
seri
congression
hear
report
govern
account
offic
iom
studi
fda
develop
hh
subsequ
adopt
comprehens
blood
action
plan
design
address
identifi
shortcom
ensur
greater
coordin
among
depart
public
health
agenc
increas
effect
fda
scientif
regulatori
activ
notabl
era
wit
aggress
effort
fda
improv
blood
safeti
enforc
cgmp
blood
product
collect
process
align
model
pharmaceut
manufactur
formal
relationship
blood
establish
experienc
past
fda
initi
also
involv
promot
autom
reduc
human
error
includ
use
valid
blood
bank
softwar
intens
program
field
inspect
design
assur
univers
regulatori
complianc
blood
collect
establish
result
number
voluntari
injunct
consent
decre
known
emerg
infecti
threat
blood
safeti
continu
demand
attent
era
repeatedli
test
whether
lesson
taa
learn
prepar
deal
potenti
threat
bioterror
agent
much
effort
expend
prepar
outbreak
chikungunya
viru
might
never
happen
pandem
influenza
middl
east
respiratori
syndrom
coronaviru
absenc
studi
establish
presenc
absenc
viremia
cours
infect
make
sens
screen
blood
donat
risk
babesiosi
dengu
season
geograph
chang
current
paradigm
donor
screen
test
consid
pathogen
reduct
becom
avail
blood
compon
gener
becom
increasingli
proactiv
address
infecti
risk
misdirect
resourc
could
better
spent
improv
blood
safeti
way
reader
commentari
encourag
ask
whether
lesson
taa
optim
incorpor
decad
challeng
respons
follow
sentinel
event
histori
blood
safeti
recognit
respons
taa
although
etiolog
remain
unknown
report
aid
three
person
hemophilia
juli
suggest
pathogen
caus
three
individu
report
heterosexu
known
aid
risk
factor
receiv
frequent
administr
factor
viii
concentr
evid
transmiss
aid
agent
blood
strengthen
decemb
report
infant
san
francisco
develop
unexplain
immunodefici
transfus
multipl
blood
product
treat
erythroblastosi
one
blood
donor
man
healthi
time
donat
subsequ
die
aid
address
possibl
aid
associ
receipt
blood
blood
product
center
diseas
control
prevent
cdc
conven
meet
januari
particip
fda
nation
hemophilia
foundat
blood
bank
offici
patient
advocaci
group
cdc
perspect
purpos
meet
discuss
reduc
risk
aid
transfus
recipi
person
hemophilia
absenc
test
etiolog
agent
sever
possibl
strategi
present
includ
deferr
blood
donat
person
known
increas
risk
aid
use
surrog
test
identifi
person
increas
risk
transmiss
detect
antibodi
hepat
b
core
antigen
low
ratio
howev
meet
turn
contenti
debat
exist
aid
transfus
recipi
person
hemophilia
agreement
reach
risk
reduct
strategi
march
us
public
health
servic
publish
first
recommend
prevent
among
recommend
statement
temporari
measur
member
group
increas
risk
aid
refrain
donat
plasma
andor
blood
addit
person
clinic
evid
aid
sexual
partner
consid
increas
risk
includ
sexual
activ
homosexu
bisexu
men
multipl
partner
haitian
entrant
unit
state
present
past
abus
iv
drug
patient
hemophilia
sexual
partner
individu
increas
risk
aid
time
recommend
controversi
particular
restrict
blood
donat
homosexu
men
seen
civil
right
issu
defer
donat
haitian
entrant
undoubtedli
led
discrimin
haitian
american
public
health
perspect
howev
measur
need
increas
blood
safeti
identif
hiv
screen
donat
blood
plasma
becam
possibl
bulk
prepar
viru
known
time
provid
nation
cancer
institut
diagnost
compani
develop
antibodi
detect
test
first
screen
test
develop
abbott
laboratori
approv
fda
march
concern
person
would
donat
blood
purpos
learn
hiv
infect
statu
cdc
fund
first
altern
hiv
test
site
individu
could
obtain
free
confidenti
test
blood
bank
also
establish
option
confidenti
unit
exclus
allow
person
donat
blood
confidenti
indic
blood
use
transfus
watersh
event
blood
safeti
statement
fda
commission
septemb
workshop
nucleic
acid
technolog
implement
close
window
period
hiv
detect
serolog
technolog
consid
costli
cumbersom
practic
applic
blood
bank
introduct
direct
test
hiv
donor
blood
first
antigen
assay
prove
larg
nucleic
acid
test
nat
viral
rna
prove
benefici
put
rest
decad
concern
residu
hiv
risk
donat
infecti
window
period
seroconvers
depend
sensit
differ
screen
test
success
adapt
nat
donor
screen
includ
test
specimen
small
pool
establish
new
era
risk
reduct
viral
diseas
addit
increas
safeti
transfus
blood
hiv
antibodi
screen
donor
led
lookback
program
recipi
previou
unscreen
donat
infect
donor
identifi
recipi
found
substanti
risk
although
effect
treatment
avail
time
infect
recipi
could
counsel
reduc
risk
hiv
transmiss
other
anoth
retroviru
also
found
caus
diseas
includ
adult
leukemia
lymphoma
associ
myelopathi
tropic
spastic
paraparesi
viru
transmit
transfus
cellular
blood
product
plasma
fraction
plasma
novemb
fda
issu
guidanc
recommend
antibodi
test
donat
whole
blood
cellular
compon
high
degre
sequenc
homolog
current
approv
screen
assay
also
detect
antibodi
viru
transmiss
rout
similar
less
clear
diseas
associ
although
fda
approv
western
blot
pcr
test
use
distinguish
two
virus
world
war
ii
led
recognit
frequent
occurr
hepat
among
militari
personnel
confluenc
contamin
water
massiv
immun
first
time
blood
transfus
time
infecti
hepat
distinguish
parenter
transmit
serum
hepat
entiti
later
term
hepat
b
respect
report
seven
case
jaundic
occur
month
transfus
blood
plasma
dramat
outbreak
hepat
involv
us
soldier
trace
prepar
yellow
fever
vaccin
conclus
document
parenter
transmiss
decad
later
outbreak
shown
seeff
due
hepat
b
viru
us
armi
extens
studi
serum
hepat
war
character
epidemiolog
result
diseas
could
identifi
caus
agent
etiolog
breakthrough
began
earli
discoveri
australia
antigen
blumberg
cowork
nation
institut
health
nih
singl
find
chang
cours
hepat
histori
australia
antigen
shown
blumberg
group
associ
viral
princ
specif
associ
hepat
b
england
dane
show
immun
electron
microscopi
australia
antigen
repres
envelop
protein
hbv
renam
hepat
b
surfac
antigen
hbsag
serolog
distinct
hepat
b
solidifi
controversi
definit
prospect
studi
krugman
willowbrook
state
school
us
govern
play
pivot
role
moment
event
first
initi
discoveri
australia
antigen
intramur
program
nih
extens
grant
support
blumberg
laboratori
institut
cancer
research
philadelphia
late
earli
prospect
studi
nih
clinic
center
reveal
sever
critic
element
tah
includ
primari
risk
factor
tah
use
paid
donor
confirm
earlier
studi
led
fda
mandat
requir
label
paid
donor
blood
effect
result
adopt
blood
collect
unpaid
volunt
one
import
infecti
diseas
intervent
ever
implementedthat
hbsag
test
blood
donor
effect
even
use
insensit
techniqu
agar
gel
diffus
counterelectrophersei
nationwid
test
hbsag
delay
practic
confirm
assay
introduc
simultan
implement
volunteer
hbsag
screen
reduc
incid
tah
approxim
massiv
reduct
depend
donor
sourc
blood
screen
hbv
shown
account
less
total
tahthat
discoveri
hepat
viru
hav
feinston
cowork
becam
evid
hav
respons
residu
case
tah
give
rise
cumbersom
nonpresumpt
design
intens
effort
isol
nanbh
agent
decad
unsuccess
studi
nih
cdc
reveal
agent
small
similar
small
rna
alpha
despit
absenc
specif
test
detect
nanbh
agent
tah
incid
declin
judici
use
blood
foster
recognit
nanbh
could
result
cirrhosi
devast
consequ
absenc
specif
nanbh
assay
surrog
assay
advoc
transfus
transmit
viru
studi
support
nation
heart
lung
blood
institut
publish
retrospect
analysi
prospect
studi
show
alanin
aminotransferas
alt
test
donor
might
effect
reduct
tah
confirm
similar
analysi
nih
prospect
tah
implement
alt
donor
screen
nih
fail
demonstr
predict
similar
retrospect
test
transfus
transmit
viru
prospect
studi
suggest
test
might
result
reduct
tah
foster
voluntari
introduct
alt
donor
test
fda
recommend
routin
donor
test
although
screen
introduc
specif
detect
hbv
carrier
hbsag
neg
term
occult
hepat
b
also
serv
surrog
nanb
carrier
seroneg
hiv
carrier
overlap
transmiss
rout
surrog
test
introduc
earli
presum
would
prevent
case
aid
nanbh
delay
implement
basi
extens
litig
also
serv
driver
iom
recommend
invok
precautionari
principl
weigh
new
donor
screen
intervent
precautionari
approach
significantli
improv
transfus
safeti
industri
play
major
role
hepat
prevent
first
develop
increasingli
sensit
assay
hbsag
develop
nucleic
acid
detect
assay
major
virus
particularli
clone
nanb
latter
monument
achiev
chiron
corpor
collabor
dan
bradley
cdc
use
techniqu
express
clone
investig
identifi
singl
clone
among
million
test
react
serum
patient
nanbh
houghton
associ
chiron
walk
genom
character
antigen
deriv
nonstructur
region
viral
genom
develop
antibodi
assay
detect
viral
studi
confirm
clone
agent
design
hepat
c
viru
hcv
detect
virtual
nanbh
case
identifi
implic
donor
near
case
test
introduc
assay
prospect
studi
nih
clinic
center
document
virtual
erad
tah
mathemat
model
introduct
nat
screen
predict
current
risk
hepat
c
approxim
one
case
everi
million
transfus
approxim
risk
hit
lightn
west
nile
viru
wnv
first
identifi
unit
state
outbreak
enceph
new
york
four
case
unexplain
fever
enceph
recipi
organ
transplant
common
donor
prove
caus
wnv
rais
possibl
transmiss
blood
transfus
initi
effort
screen
blood
donor
use
sign
symptom
wnv
infect
prove
total
case
human
ill
report
least
peopl
contract
wnv
transfus
six
rapid
expans
wnv
across
unit
state
report
botsec
cdc
lent
urgenc
develop
screen
test
next
epidem
fda
request
industri
develop
test
nation
heart
lung
blood
institut
provid
million
research
support
american
red
cross
provid
archiv
specimen
fda
facilit
rapid
nation
test
implement
ultim
approv
although
develop
blood
screen
test
usual
take
year
nat
assay
wnv
avail
epidem
season
build
technolog
platform
alreadi
develop
hiv
hcv
west
nile
viru
first
acut
infect
short
asymptomat
viremia
epidem
spread
warrant
routin
donor
test
demonstr
success
collabor
govern
blood
collector
diagnost
footnot
wnv
screen
success
recognit
test
pool
sampl
insuffici
sensit
detect
viremia
blood
donat
includ
infecti
preseroconvers
donat
commonli
encount
epidem
spread
howev
univers
test
individu
unit
nonepidem
area
nationwid
ineffici
costli
problem
solv
novel
strategi
trigger
individu
test
base
yield
pool
test
approach
effect
detect
interdict
approxim
potenti
infecti
blood
donat
emerg
variant
diseas
vcjd
unit
kingdom
franc
first
report
pose
arguabl
challeng
blood
safeti
problem
decis
maker
sinc
begin
aid
epidem
like
aid
vcjd
present
new
diseas
unknown
transmiss
dynam
potenti
transmiss
blood
transfus
recognit
novel
infecti
agent
prion
near
invari
vcjd
link
bovin
spongiform
encephalopathi
diseas
recogn
unit
kingdom
sinc
incub
period
diseas
assum
lengthi
scope
epidem
remain
prion
unlik
bacteria
virus
technolog
develop
diagnost
screen
assay
avail
fda
establish
transmiss
spongiform
encephalopathi
advisori
committe
assur
focus
object
transpar
input
decis
make
base
avail
epidemiolog
data
fda
recommend
blood
compon
collect
donor
diagnos
vcjd
withdrawn
develop
mathemat
model
indefinit
donor
deferr
base
geograph
exposur
donor
resid
unit
kingdom
total
month
elimin
estim
donor
bovin
spongiform
encephalopathi
unit
kingdom
project
loss
approxim
donor
consid
difficult
balanc
safeti
suppli
necessit
close
monitor
blood
base
continu
surveil
vcjd
geograph
exclus
expand
provid
approxim
reduct
total
donor
exposur
bovin
spongiform
encephalopathi
western
europ
includ
unit
kingdom
estim
total
donor
loss
approxim
question
blood
transmiss
answer
unit
kingdom
report
four
case
vcjd
infect
associ
blood
transfus
occur
four
recipi
receiv
transfus
nonleukoreduc
rbc
confirm
long
incub
time
tell
whether
step
taken
unit
state
prove
warrant
suffici
polici
reflect
adopt
partial
solut
appear
reduc
risk
attempt
act
expediti
respons
model
address
risk
face
scientif
uncertainti
chaga
diseas
caus
protozoa
trypanosoma
cruzi
affect
estim
million
peopl
global
estim
peopl
unit
state
canada
infect
infect
found
immigr
latin
america
wherea
new
infect
vector
born
transmiss
blood
transfus
well
recogn
six
transmiss
report
unit
state
abil
screen
blood
earli
fda
blood
product
advisori
committe
recogn
infect
cruzi
develop
symptomat
diseas
infect
lifelong
absenc
earli
treatment
view
increas
immigr
unit
state
endem
region
blood
product
advisori
committe
recommend
test
donor
suitabl
test
becam
avail
donor
histori
screen
prove
insuffici
sensit
specif
test
found
suitabl
licensur
shortli
thereaft
major
blood
collector
undertook
univers
donor
screen
antibodi
cruzi
retrospect
earlier
studi
lo
angel
miami
suggest
seroposit
equat
infect
none
recipi
blood
subsequ
identifi
seroposit
donor
evid
two
year
screen
unit
state
establish
wherea
seropreval
may
high
donor
region
infect
confirm
lookback
studi
reexamin
fda
decis
recommend
univers
donor
screen
led
novel
polici
donor
test
base
demonstr
rariti
acut
incid
cruzi
infect
us
donor
anthrax
caus
infect
bacterium
bacillu
anthraci
found
global
temper
zone
uncommon
unit
seven
case
cutan
anthrax
report
cdc
outbreak
anthrax
result
confirm
suspect
case
includ
five
episod
rais
public
concern
blood
suppli
period
high
anxieti
regard
threat
bioterror
bacteremia
present
fulmin
cutan
respiratori
anthrax
howev
bacteremia
asymptomat
individu
describ
period
exposur
b
anthraci
develop
clinic
anthrax
report
day
may
long
day
littl
inform
exist
regard
transmiss
via
blood
transfus
asymptomat
individu
expos
b
anthraci
case
report
licens
diagnost
blood
donor
screen
test
exist
fda
receiv
sever
inquiri
regard
risk
blood
suppli
donor
direct
contact
materi
contamin
b
anthraci
consult
expert
cdc
nih
us
armi
medic
research
institut
infecti
diseas
fda
issu
guidanc
regard
measur
reduc
possibl
risk
transmiss
anthrax
guidanc
recommend
chang
standard
donor
screen
blood
collect
procedur
emphas
standard
blood
collect
procedur
alreadi
place
includ
deferr
donor
good
health
time
donat
nevertheless
address
public
concern
well
dearth
scientif
inform
regard
blood
transmiss
fda
provid
prudent
specif
recommend
concern
donor
confirm
medic
diagnosi
anthrax
proven
colon
b
anthraci
provid
criteria
product
quarantin
retriev
relat
report
postdon
journal
scienc
report
gamma
retroviru
xenotrop
murin
leukemia
viru
xmrv
isol
blood
patient
diagnos
chronic
fatigu
syndrom
cf
alarmingli
healthi
second
articl
report
relat
retroviru
pmlv
even
higher
preval
among
blood
report
gener
enorm
public
interest
concern
given
possibl
xmrv
could
transmit
transfus
immedi
call
aros
screen
blood
donor
sign
symptom
cf
test
donat
xmrv
time
intens
effort
undertaken
worldwid
resolv
potenti
safeti
concern
feder
interag
work
group
met
repeatedli
teleconfer
electron
commun
laboratori
within
cdc
nih
fda
invest
resourc
investig
discrep
laboratori
addit
repres
cdc
fda
extramur
program
nih
particip
interorganiz
task
forc
assembl
within
day
aabb
formerli
american
associ
blood
bank
result
voluntari
implement
interim
aabb
recommend
blood
collector
activ
discourag
potenti
donor
diagnos
physician
cf
chronic
fatigu
immun
dysfunct
syndrom
myalgic
encephalomyel
donat
blood
ultim
definit
laboratori
evid
xmrv
pmlv
bore
associ
cf
pose
threat
blood
sever
infecti
threat
current
challeng
feder
decis
maker
bacteri
contamin
platelet
clearli
identifi
risk
address
partial
solut
cultur
serolog
hepat
e
viru
known
transfus
transmit
potenti
diseas
burden
geograph
travel
exclus
limit
risk
malaria
transmiss
continu
refin
pend
develop
screen
assay
pathogen
reduct
technolog
surveil
coronavirus
respons
sever
acut
respiratori
syndrom
middl
east
respiratori
syndrom
activ
possibl
agent
well
pandem
influenza
monkey
pox
might
transfus
transmit
disrupt
blood
donat
unresolv
possibl
season
donor
screen
valid
test
dengu
babesiosi
model
even
pilot
studi
screen
assay
pathogen
reduct
technolog
offer
altern
approach
risk
mitig
technolog
would
chang
paradigm
known
infecti
agent
like
threaten
blood
suppli
feder
decis
maker
involv
determin
technolog
appli
nation
blood
blood
compon
feder
respons
infect
evolv
dramat
sinc
emerg
hiv
infect
philosophi
risk
manag
becom
precautionari
patient
focus
yet
still
data
driven
regul
blood
collector
becom
formal
stringent
manufactur
blood
compon
held
account
meet
cgmp
standard
similar
appli
manufactur
medic
devic
drug
new
arguabl
respons
feder
structur
address
issu
blood
safeti
avail
adopt
structur
place
premium
clear
line
author
intern
public
commun
flexibl
coordin
among
feder
agenc
major
role
blood
safeti
feder
agenc
encourag
public
discours
workshop
joint
initi
industri
particip
partnership
profession
societi
blood
collector
adjust
allow
feder
agenc
respond
appropri
urgenc
differ
situat
pose
emerg
infecti
agent
era
sinc
recognit
taa
year
none
